Literature DB >> 8892954

A simple reverse transcriptase PCR assay to distinguish EBNA1 gene transcripts associated with type I and II latency from those arising during induction of the viral lytic cycle.

B C Schaefer1, J L Strominger, S H Speck.   

Abstract

In Epstein-Barr virus (EBV)-associated tumors that arise in immunocompetent individuals, the pattern of viral gene expression is very restricted compared with that of latently infected B cells in tissue culture. A hallmark of viral gene expression in these tumors is the exclusive expression of only one EBV-encoded nuclear antigen, EBNA1, which is driven from a promoter (Qp) that lies near the junction of the viral BamHI F and Q fragments. During induction of the lytic cycle, a viral promoter, Fp, which lies ca. 200 bp upstream of Qp, gives rise to transcripts which overlap with Qp-initiated EBNA1 gene transcripts. Distinguishing between latency-associated EBNA1 gene transcripts and those associated with the early phase of the viral lytic cycle is critical for correct identification of restricted viral latency. Here we describe a reverse transcriptase PCR protocol which employs a nested set of upstream primers from the BamHI Q region of the viral genome and readily distinguishes Fp-initiated transcripts from Qp-initiated transcripts. A single set of amplification conditions was used for the various PCR primer combinations, which allowed all reactions to be run simultaneously. An in vitro-generated transcript, diluted in RNA from an EBV-negative cell line, was used to demonstrate that the efficiencies of amplification with the different primer combinations were very similar. This protocol was used to demonstrate that EBNA1 gene transcription in two previously uncharacterized EBV-positive epithelial cell lines initiates from Qp. In addition, we assessed the site(s) of initiation of EBNA1 gene transcripts in cell lines exhibiting restricted viral latency. Contrary to the results of Nonkwelo et al. (J. Virol. 70:623-627, 1996), which indicated that EBNA1 gene transcription during restricted viral latency initiates at multiple sites downstream of Fp, we show here that nearly all EBNA1 transcripts start at the previously identified Qp transcription initiation site.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892954      PMCID: PMC190903     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  Transcription of Epstein-Barr virus genomes in human lymphoblastoid cells and in somatic-cell hybrids of Burkitt's lymphoma.

Authors:  M Nonoyama; A Tanaka; S Silver; R Glaser
Journal:  IARC Sci Publ       Date:  1978

3.  Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

Authors:  J Levitskaya; M Coram; V Levitsky; S Imreh; P M Steigerwald-Mullen; G Klein; M G Kurilla; M G Masucci
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

4.  Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.

Authors:  G Klein; L Dombos; B Gothoskar
Journal:  Int J Cancer       Date:  1972-07-15       Impact factor: 7.396

5.  The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

6.  Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

7.  Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.

Authors:  C Nonkwelo; J Skinner; A Bell; A Rickinson; J Sample
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Establishment of Epstein-Barr virus (EBV)-associated nuclear antigen (EBNA)-positive nasopharyngeal carcinoma hybrid cell line (NPC-KT).

Authors:  T Takimoto; M Kamide; R Umeda
Journal:  Arch Otorhinolaryngol       Date:  1984

9.  Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance.

Authors:  C M Rooney; M Rowe; L E Wallace; A B Rickinson
Journal:  Nature       Date:  1985 Oct 17-23       Impact factor: 49.962

10.  Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.

Authors:  E M Deacon; G Pallesen; G Niedobitek; J Crocker; L Brooks; A B Rickinson; L S Young
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  10 in total

1.  Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.

Authors:  Donna Hochberg; Jaap M Middeldorp; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

2.  Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers.

Authors:  Kevin N Heller; Jenica Upshaw; Beza Seyoum; Henry Zebroski; Christian Münz
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

3.  Activity of the EBNA1 promoter associated with lytic replication (Fp) in Epstein-Barr virus associated disorders.

Authors:  A A Brink; C J Meijer; J M Nicholls; J M Middeldorp; A J van den Brule
Journal:  Mol Pathol       Date:  2001-04

4.  The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive.

Authors:  Q Tao; K D Robertson; A Manns; A Hildesheim; R F Ambinder
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

5.  Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

6.  Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.

Authors:  B C Schaefer; E Paulson; J L Strominger; S H Speck
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

7.  Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.

Authors:  G J Babcock; L L Decker; R B Freeman; D A Thorley-Lawson
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

8.  Nanoparticle exposure reactivates latent herpesvirus and restores a signature of acute infection.

Authors:  Christine Sattler; Franco Moritz; Shanze Chen; Beatrix Steer; David Kutschke; Martin Irmler; Johannes Beckers; Oliver Eickelberg; Philippe Schmitt-Kopplin; Heiko Adler; Tobias Stoeger
Journal:  Part Fibre Toxicol       Date:  2017-01-10       Impact factor: 9.400

Review 9.  Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome.

Authors:  Manuel Ruiz-Pablos; Bruno Paiva; Rosario Montero-Mateo; Nicolas Garcia; Aintzane Zabaleta
Journal:  Front Immunol       Date:  2021-11-15       Impact factor: 7.561

10.  Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection.

Authors:  Elisabeth Amyes; Chris Hatton; Damien Montamat-Sicotte; Nancy Gudgeon; Alan B Rickinson; Andrew J McMichael; Margaret F C Callan
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.